Conference Reports for NATAP

EASL 2024 June 5-8, Milan, Italy Back

Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated liver cirrhosis in the open-label, long-term ASSURE safety study: interim results       EASL 2024 June 5-8